Related Experiment Video
Updated: Sep 28, 2026

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene
Published on: December 31, 2014
MdmX inhibits Smad transactivation
Madhavi Kadakia1, Thomas L Brown, Molly M McGorry
1Department of Biochemistry and Molecular Biology, Wright State University, Dayton, Ohio, USA.
Abstract:
Mdm2 overexpression confers a growth promoting activity upon cells primarily by downregulating the p53 tumor suppressor protein. Nevertheless, Mdm2 deregulation has also been implicated in inhibiting TGF-beta growth repression in a p53 independent manner. Our goal in this study was to examine whether overexpression of Mdm2 or MdmX, a Mdm2-related protein, could affect Smad-induced transactivation. As downstream signaling elements of the TGF-beta pathway, Smads represent one potential target for Mdm2 and MdmX. Here we show that MdmX but not Mdm2 is capable of inhibiting Smad induced transactivation. Based on deletion mutant analysis, MdmX inhibition of Smad transactivation was independent of the p53 and Mdm2 interaction domains, yet required amino acid residues 128-444. Using TGF-beta sensitive HepG2 cells, MdmX overexpression was shown to inhibit TGF-beta induced Smad transactivation. Additionally, mouse embryo fibroblasts (MEFs) lacking p53 and MdmX showed enhanced Smad transactivation when compared to MEFs lacking either p53 or p53 and Mdm2. Interestingly, the inhibition of Smad transactivation by MdmX could be reversed by p300, a functional co-activator of Smads and a necessary factor for Mdm2 nuclear export and did not result from altered Smad localization. In vitro studies demonstrate that MdmX binds to p300 as well as Smad3 and Smad4. Taken together, these results suggest that inhibition of Smad-induced transactivation by MdmX occurs by altering Smad interaction with its coactivator p300.
Insights
MdmX protein inhibits Smad-induced transactivation, a key part of TGF-beta signaling, by interacting with the coactivator p300. This finding offers new insights into cancer growth regulation pathways.
Area of Science:
- Molecular Biology
- Cell Signaling
- Cancer Research
Background:
- Mdm2 overexpression promotes cell growth by downregulating p53.
- Mdm2 deregulation can inhibit TGF-beta growth repression independently of p53.
- Smads are key downstream signaling elements of the TGF-beta pathway.
Purpose of the Study:
- To investigate if Mdm2 or MdmX overexpression affects Smad-induced transactivation.
- To determine the mechanism by which MdmX influences Smad activity.
Main Methods:
- Deletion mutant analysis of MdmX.
- Overexpression studies in TGF-beta sensitive HepG2 cells.
- Analysis of Smad transactivation in mouse embryo fibroblasts (MEFs) lacking p53 and/or MdmX.
- In vitro binding assays.
Main Results:
- MdmX, but not Mdm2, inhibits Smad-induced transactivation.
- MdmX inhibition requires amino acid residues 128-444 and is independent of p53 and Mdm2 interaction domains.
- MdmX overexpression inhibits TGF-beta induced Smad transactivation in HepG2 cells.
- MEFs lacking p53 and MdmX show enhanced Smad transactivation compared to other knockout lines.
- p300 reverses MdmX-mediated inhibition of Smad transactivation.
- MdmX binds to p300, Smad3, and Smad4.
Conclusions:
- MdmX inhibits Smad-induced transactivation through a mechanism involving its interaction with the coactivator p300.
- This interaction likely alters the ability of Smads to interact with p300, impacting TGF-beta signaling.
- The findings suggest a novel role for MdmX in regulating TGF-beta pathway activity, independent of its interaction with p53.
Related Concept Videos
TGF - β Signaling Pathway
Abnormal Proliferation
Master Transcription Regulators
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
The JAK-STAT Signaling Pathway
Co-activators and Co-repressors

